Project Grant R01HL187148
Award Date 8/15/26
Completion Date 5/31/30
Dollars Obligated $769K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Trustees of Boston University (doing business as Boston University Medical Campus) $837,000 in project grant funding on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into lung-specific mechanisms that enable Mycobacterium tuberculosis survival and progression in immunocompetent hosts. The project examines how dysplastic epithelial cells within pulmonary tuberculosis lesions...
- The National Heart, Lung, and Blood Institute awarded The Washington University $680,379 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of sphingolipid biosynthesis during lung infection, specifically examining how SPTLC2, an essential enzyme subunit in sphingolipid synthesis, affects survival during Mycobacterium tuberculosis infection in CD11C+ lung macrophages and dendritic cells. The project addresses immune response mechanisms...
- The National Heart, Lung, and Blood Institute awarded Oregon Health & Science University $218,728 in project grant funding on March 18, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). This award funds spatial immunophenotyping of tuberculosis granulomas, with work performed at OHSU's Portland, Oregon campus through September 16, 2029. The project applies an extensive panel of Mycobacterium tuberculosis antigen-specific probes—including commercial antibodies, novel...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $787,297 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 4, 2026. The award funds research into vascular dysfunction and lung allograft health, specifically investigating the mechanisms of primary graft dysfunction (PGD)—an ischemia-reperfusion injury that occurs in approximately 35 percent of lung transplants. The research examines how inflammasome-mediated pyroptosis and endothelial...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $1.102 million in funding under the Cardiovascular Diseases Research program (CFDA 93.837) on July 1, 2026, for a Project Grant (R35HL182842) supporting research into the regulation of ubiquitin E3 ligases and innate immunity in acute respiratory distress syndrome (ARDS). The research investigates immunosuppressive F-box proteins that degrade key substrates essential for host innate immunity and cytoprotective...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded Emory University $123,654 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct mentoring in patient-oriented translational research on tuberculosis, HIV, and lung health (Project Grant K24HL189236). The award funds research to identify risk factors for post-TB lung disease (PTLD) and develop evidence-based interventions to prevent PTLD and improve long-term respiratory health among TB...
- The National Institute of Allergy and Infectious Diseases awarded the Trustees of Boston University $245,250 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study the phenotypes and genesis of arginase 1-positive myeloid cells in pulmonary tuberculosis using a genetic mouse model of chronic TB. The research uses the B6.SST1S mouse model, which develops human-like organized necrotic granulomas after aerosol, intravenous, or subcutaneous infection...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts General Hospital $798,107 on February 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish a tissue-based understanding of tuberculosis-associated lung fibrosis and post-TB lung disease pathology. The project creates a baseline understanding of molecules and cells driving fibrogenesis during TB infection, with the goal of identifying adjunctive therapies to modulate tissue...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $1,574,578 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel targeted modified mRNA delivery strategies for donation after circulatory death (DCD) heart transplantation. The research addresses primary graft dysfunction (PGD), an ischemia-reperfusion injury occurring in approximately 35 percent of heart transplants and driven by hyper-inflammatory responses involving...
- The National Heart, Lung, and Blood Institute awarded Boston University a Project Grant of $1,605,354 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lung interstitial macrophages and their role in bacterial pneumonia defense. The research examines two major subsets of lung interstitial macrophages—CD206+ and CD206—that occupy distinct anatomic niches and perform different immune functions. Preliminary findings indicate that both subsets...